LENZ Therapeutics (LENZ) Current Assets (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Current Assets data on file, last reported at $268.4 million in Q1 2026.

• On a quarterly basis, Current Assets rose 35.64% year-over-year to $268.4 million in Q1 2026; TTM through Mar 2026 was $268.4 million, a 35.64% increase from a year earlier, with the FY2025 full-year figure at $301.4 million, up 42.23% from the prior year.
• Current Assets for Q1 2026 stood at $268.4 million, down from $301.4 million in the prior quarter.
• Over the last five years, Current Assets for LENZ reached as high as $343.8 million in Q1 2022 and fell as low as $67.2 million in Q4 2023.
• Historically, Current Assets has averaged $241.7 million across 5 years, with a median of $238.8 million in 2023.
• Across the five-year window, Current Assets slumped 75.58% in 2023 and jumped 215.15% in 2024, its largest moves.
• Year by year, Current Assets stood at $275.4 million in 2022, then slumped by 75.58% to $67.2 million in 2023, then soared by 215.15% to $211.9 million in 2024, then surged by 42.23% to $301.4 million in 2025, then dropped by 10.96% to $268.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $268.4 million in Q1 2026, $301.4 million in Q4 2025, and $207.0 million in Q3 2025.